Terazosin
ترازوسین
🚻 Genito Urinary System And Sex HormonesAlpha-1 blocker
Market / country: 🇺🇸 USA
Hytrin (US)
🧮 Dose calculator
Benign prostatic hyperplasia (BPH) · Regimen source: FDA Terazosin · Dosage and Administration
- • Do not exceed 1 mg as the first dose. 10 mg is usually needed; assess response after 4–6 weeks; data at 20 mg are limited. Restart at 1 mg after a break of several days. FDA Terazosin · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to terazosin. FDA Terazosin · Contraindications
Warnings
- • Syncope and first-dose hypotension. FDA Terazosin · Warnings
Formulations
- 1 mg capsule — capsule 🇺🇸 USA FDA Terazosin · How Supplied
- 2 mg capsule — capsule 🇺🇸 USA FDA Terazosin · How Supplied
- 5 mg capsule — capsule 🇺🇸 USA FDA Terazosin · How Supplied
- 10 mg capsule — capsule 🇺🇸 USA FDA Terazosin · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Terazosin · Pregnancy
“Teratogenic Effects Pregnancy Category C Terazosin capsules were not teratogenic in either rats or rabbits when administered at oral doses up to 280 and 60 times, respectively, the maximum recommended human dose.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Terazosin · Nursing Mothers
“Because many drugs are excreted in breast milk, caution should be exercised when terazosin capsules are administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Terazosin · Pediatric Use
“Safety and effectiveness in pediatric patients have not been determined.”
- 👴 Older adultsNo data
The source for this drug has no section for this group.
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA074823
- DailyMed (FDA label)FDA Terazosin
- MedlinePlus (NIH)Terazosin
- WHO ATC/DDDG04CA03
- Darooyab (Iran)Terazosin
🇮🇷 Registered in Iran Darooyab · G-1902/Terazosin
Dosage forms with Iranian generic codes, per Darooyab.
- 01892 · TERAZOSIN 2MG TAB · قرص ترازوسین ۲ میلیگرم
- 01893 · TERAZOSIN 5MG TAB · قرص ترازوسین ۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Terazosin · How SuppliedFDA Terazosin · Dosage and AdministrationFDA Terazosin · ContraindicationsFDA Terazosin · WarningsFDA Terazosin · PregnancyFDA Terazosin · Nursing MothersFDA Terazosin · Pediatric UseFDA Terazosin · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1902/Terazosin
- Clinical review⚠ Unverified